Form 4: Exelixis CEO Michael Morrissey Reports Stock Transaction Following Vesting of Restricted Stock Units
SEC Form 4 Filing
Exelixis CEO Michael Morrissey sold 47,642 shares to cover taxes related to vested performance-based restricted stock units, while still holding a significant number of shares directly and indirectly.
Summary
- Michael Morrissey, the President and CEO of Exelixis, Inc., reported a transaction involving the company's common stock.
- On November 15, 2024, 47,642 shares were disposed of to cover tax obligations related to the vesting of performance-based restricted stock units.
- These restricted stock units were initially awarded on October 22, 2020, and the performance criteria were certified on September 6, 2023.
- Following the transaction, Morrissey directly owns 916,742 shares and indirectly owns 1,407,212 shares through a family trust and 17,728 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation. There is no indication of positive or negative sentiment.
Industry Context
This is a routine filing related to executive compensation and stock ownership, common in publicly traded companies. It does not indicate any unusual activity or trend within the biotech industry.
Comparison to Industry Standards
- Stock transactions by executives are a common occurrence in publicly traded companies, particularly following the vesting of equity awards.
- The sale of shares to cover tax obligations is a standard practice and does not necessarily reflect a negative outlook on the company's future.
- Similar transactions are regularly reported by executives at comparable biotech companies such as Gilead Sciences, Amgen, and Biogen.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
- The transaction does not impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2020-10-22 | Date of initial award of performance-based restricted stock units. |
| 2023-09-06 | Date the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria. |
| 2024-11-14 | Date of the 401(k) plan statement. |
| 2024-11-15 | Date of the stock transaction. |
| 2024-11-19 | Date of the filing of the SEC Form 4. |
Keywords
Exelixis, Michael Morrissey, stock transaction, restricted stock units, SEC Form 4, insider trading, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.